| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_470a3cf04bb3bc920c36e851e7cc595d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f5d451868a10b6e42a7b14612b1ab12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdf813fcbab1efe5ffda06dcb90db3af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b2d38ad6bd11ed4057f367b80a3682a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04e3ea791d6b07c551730ed0cc66f3d5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-026 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2008-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59f78c0e278963c212149a376cac0637
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e97a57c80aa35ffacfbb57c6e1bef94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31044e3e913d8784ef1e8806d4921006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_625bc08232d6931fddbe20b3ab8514aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1dbbd52d3ba04a5ea139c9666323cd5 |
| publicationDate |
2009-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009220501-A1 |
| titleOfInvention |
Anti-CD19 Antibody, Immunotoxin and Treatment Method |
| abstract |
Provided is an immunotoxin including (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein having both Domains II and III, but lacking Domain I, and (c) a peptide linker joining the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A protein. The linker is substantially resistant to extracellular cleavage. The modified exotoxin A protein may be further modified to include a C-terminal KDEL sequence (SEQ ID NO: 6) that promotes transport of the protein to the endoplasmic reticulum of cells that have taken up the immunotoxin. Also provided is an anti-CD19 antibody having enhanced binding activity, antibody-dependent cellular cytotoxicity (ADCC) and methods for using the antibody to treat a disease state associated with B-lineage cells that express CD19. The antibody variable light and variable heavy chains have unique sequences in their J region relative to known anti-CD19 antibody sequences. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111848801-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015283261-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I800824-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016176651-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3747472-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9623117-B2 |
| priorityDate |
2006-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |